4Q'25 vs. 4Q'24 Results Sales: € 315.12 M (+3.1% vs. +0.1% BS(e) and +2.2% consensus); EBITDA: € 71.75 M (-9.1% vs. +0.7% BS(e) and -2.3% consensus). FY2025 vs. FY2024 Results Sales: € 1.252 Bn (+4.0% vs. +3.2% BS(e) and +3.8% consensus); EBITDA: € 289.99 M (+1.6% vs. +4.3% BS(e) and +3.5% consensus).
Rdos. 4T'25 vs 4T'24: Ventas: 2.649 M euros (+5,1% vs +4,2% BS(e)); EBITDA: 360,5 M euros (-19,8% vs -1,6% BS(e)); Rdos. 2025 vs 2024: Ventas: 9.700 M euros (+6,9% vs +6,7% BS(e)); EBITDA: 1.419 M euros (-1,1% vs +4,6% BS(e)); EBIT: 594,5 M euros (-18,0% vs -1,0% BS(e));
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, ACERINOX, AMADEUS, CELLNEX, COLONIAL, ELECTRICITY SECTOR, FCC, GLOBAL DOMINION, GRIFOLS, IAG, MERLIN, OHLA, REDEIA, SACYR, SOLARIA, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Doubts continue to plague Nasdaq, but software rallies after harsh punishment European s...
A director at Metrovacesa S.A. sold 20,000 shares at 13.020EUR and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, ACERINOX, AMADEUS, CELLNEX, COLONIAL, FCC, GLOBAL DOMINION, GRIFOLS, IAG, MERLIN, OHLA, REDEIA, S. ELÉCTRICO, SACYR, SOLARIA, VISCOFAN. EUROPA:.n/a. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Siguen las dudas en e...
4Q'25 vs. 4Q'24 Results Sales: € 13.095 Bn (+9.8% vs. +10.7% BS(e) and +11.1% consensus); EBITDA: € 853.0 M (+9.8% vs. +6.9% BS(e) and +11.6% consensus); EBIT: € 603.0 M (+18.0% vs. +17.8% BS(e) and +6.7% consensus); Net Profit: € 295.0 M (+32.3% vs. +14.3% BS(e) and +20.1% consensus); FY2025 vs. FY2024 Results Sales: € 49.848 Bn (+19.7% vs. +20.0% BS(e) and +20.1% consensus); EBITDA: € 3.07 Bn (+25.0% vs. +24.1% BS(e) and +25.6% consensus); EBIT: € 2.1 Bn (+32.1% vs. +32.0% BS(e) and +28.4% con...
4Q'25 vs. 4Q'24 Results Sales: € 2.715 Bn (+8.4% vs. +7.3% BS(e) and +0.2% consensus); EBITDA: € 426.0 M (+27.5% vs. +12.8% BS(e) and +12.0% consensus); EBIT: € 276.0 M (+305.9% vs. +293.9% BS(e) and +293.1% consensus); FY2025 vs. FY2024 Results Sales: € 9.627 Bn (+5.2% vs. +4.9% BS(e) and +3.0% consensus); EBITDA: € 1.457 Bn (+8.6% vs. +4.9% BS(e) and +4.7% consensus); EBIT: € 967.0 M (+7.3% vs. +6.4% BS(e) and +6.4% consensus);
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.